BRPI0509454A - derivados de 4-amino-5-cianopirimidina - Google Patents

derivados de 4-amino-5-cianopirimidina

Info

Publication number
BRPI0509454A
BRPI0509454A BRPI0509454-2A BRPI0509454A BRPI0509454A BR PI0509454 A BRPI0509454 A BR PI0509454A BR PI0509454 A BRPI0509454 A BR PI0509454A BR PI0509454 A BRPI0509454 A BR PI0509454A
Authority
BR
Brazil
Prior art keywords
amino
derivatives
adenosine
cyanopyrimidine
cyanopyrimidine derivatives
Prior art date
Application number
BRPI0509454-2A
Other languages
English (en)
Inventor
Masaya Kato
Norifumi Sato
Minoru Okada
Tetsuyuki Uno
Nobuaki Ito
Yasuhiro Takeji
Hisashi Shinohara
Masahiro Fuwa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BRPI0509454A publication Critical patent/BRPI0509454A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS DE 4-AMINO-5-CIANOPIRIMIDINA A presente invenção refere-se a derivados de 4-amino-5- cianopirimidinas da fórmula: onde R¬ 1¬, R¬ 2¬ e R¬ 3¬ são definidos aqui, ou sais farmaceuticamente aceitáveis destes, tendo uma atividade agonística do receptor de adenosina A2a segura e potente; e também fornece um agonista do receptor de adenosina A2a, um agente de redução de pressão intraocular, ou um medicamento para tratamento de glaucoma, etc., que compreende o composto como um ingrediente ativo.
BRPI0509454-2A 2004-04-30 2005-04-28 derivados de 4-amino-5-cianopirimidina BRPI0509454A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004135999 2004-04-30
PCT/JP2005/008568 WO2005105778A2 (en) 2004-04-30 2005-04-28 4-amino-5-cyanopyrimidine derivatives

Publications (1)

Publication Number Publication Date
BRPI0509454A true BRPI0509454A (pt) 2007-09-04

Family

ID=35242255

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509454-2A BRPI0509454A (pt) 2004-04-30 2005-04-28 derivados de 4-amino-5-cianopirimidina

Country Status (21)

Country Link
US (2) US7834002B2 (pt)
EP (1) EP1740574B1 (pt)
KR (1) KR101279689B1 (pt)
CN (1) CN1976922B (pt)
AR (1) AR049085A1 (pt)
AT (1) ATE365731T1 (pt)
AU (1) AU2005238391B2 (pt)
BR (1) BRPI0509454A (pt)
CA (1) CA2563846C (pt)
CY (1) CY1106764T1 (pt)
DE (1) DE602005001508T2 (pt)
DK (1) DK1740574T3 (pt)
ES (1) ES2288744T3 (pt)
MX (1) MXPA06012639A (pt)
MY (1) MY138996A (pt)
PL (1) PL1740574T3 (pt)
PT (1) PT1740574E (pt)
RU (1) RU2386628C2 (pt)
SI (1) SI1740574T1 (pt)
TW (1) TWI346109B (pt)
WO (1) WO2005105778A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2089016A4 (en) * 2006-10-03 2014-10-08 Univ Pennsylvania METHOD FOR TREATING MACULAR AGENCY
TWI452044B (zh) 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
BRPI0906023A2 (pt) * 2008-03-19 2015-06-30 Bayer Cropscience Ag "composto derivado de hidroximoiltetrazol, compostos e método de controle dos fungos fitopatogênicos ou insetos daninhos de plantas, safras ou sementes"
AR075196A1 (es) * 2009-02-03 2011-03-16 Otsuka Pharma Co Ltd Un derivado de cianopirimidina para el tratamiento de una enfermedad ocular
PL2807178T3 (pl) * 2012-01-26 2017-12-29 Inotek Pharmaceuticals Corporation Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania
US9382188B2 (en) * 2012-02-13 2016-07-05 Takeda Pharmaceutical Company Limited Aromatic ring compound
US11629139B2 (en) 2017-09-08 2023-04-18 President And Fellows Of Harvard College Small molecule inhibitors of Ebola and Lassa fever viruses and methods of use
WO2019072143A1 (zh) * 2017-10-11 2019-04-18 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用
WO2025038781A1 (en) * 2023-08-15 2025-02-20 Lucy Therapeutics, Inc. Adenosine ligands for the treatment of neurological disorders or chronic heart failure

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6299395A (ja) 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
DE68916036T2 (de) 1988-11-15 1994-09-29 Toa Eiyo Ltd Mittel zur behandlung und prophylaxe koronarer und zerebraler ischämischer erkrankungen.
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
SE9703378D0 (sv) 1997-09-18 1997-09-18 Astra Ab New compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
AR017457A1 (es) 1998-02-14 2001-09-05 Glaxo Group Ltd Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
EA200001224A1 (ru) 1998-06-23 2001-08-27 Глаксо Груп Лимитед Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
JP2002173427A (ja) 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物
BR9914526A (pt) 1998-10-16 2001-07-03 Pfizer Derivados de adenina
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
IL147194A0 (en) 1999-06-22 2002-08-14 Cv Therapeutics Inc Thiophene a2a receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6180615B1 (en) 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
DE10110438A1 (de) 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10110754A1 (de) * 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115922A1 (de) 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de) 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10134481A1 (de) * 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
JP2003055395A (ja) 2001-08-10 2003-02-26 Toa Eiyo Ltd アデノシン誘導体
DE10238113A1 (de) 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
JP2003206230A (ja) 2002-01-10 2003-07-22 Yamanouchi Pharmaceut Co Ltd シアノヘテロ環誘導体又はその塩

Also Published As

Publication number Publication date
TW200540161A (en) 2005-12-16
US20110009620A1 (en) 2011-01-13
HK1100775A1 (en) 2007-09-28
US7834002B2 (en) 2010-11-16
US20080182854A1 (en) 2008-07-31
WO2005105778A3 (en) 2006-10-26
MXPA06012639A (es) 2006-12-15
AU2005238391A1 (en) 2005-11-10
WO2005105778A2 (en) 2005-11-10
EP1740574A2 (en) 2007-01-10
SI1740574T1 (sl) 2007-12-31
EP1740574B1 (en) 2007-06-27
KR20070008715A (ko) 2007-01-17
RU2386628C2 (ru) 2010-04-20
RU2006142323A (ru) 2008-06-10
KR101279689B1 (ko) 2013-06-27
CY1106764T1 (el) 2012-05-23
AR049085A1 (es) 2006-06-28
PT1740574E (pt) 2007-09-06
ES2288744T3 (es) 2008-01-16
US7989446B2 (en) 2011-08-02
AU2005238391B2 (en) 2010-12-16
CN1976922B (zh) 2012-09-05
MY138996A (en) 2009-08-28
CN1976922A (zh) 2007-06-06
PL1740574T3 (pl) 2007-11-30
CA2563846A1 (en) 2005-11-10
DE602005001508T2 (de) 2008-02-28
CA2563846C (en) 2011-12-20
DK1740574T3 (da) 2007-10-15
TWI346109B (en) 2011-08-01
ATE365731T1 (de) 2007-07-15
DE602005001508D1 (de) 2007-08-09

Similar Documents

Publication Publication Date Title
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
BRPI0418082A (pt) antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a
BRPI0606397A (pt) derivados de 1-tio-d-glucitol
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
NO20082445L (no) Neuropeptid-2 reseptor-agonister
BRPI0708038B8 (pt) derivado de cumarina, composição farmacêutica e agente terapêutico para um distúrbio proliferativo celular
BR9912098A (pt) Derivado de tiobenzimidazol, composição farmacêutica, e, agente preventivo e/ou terapêutico
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
NO20073719L (no) Kjemiske forbindelser
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
BR0208373A (pt) Inibidores da tirosina cinase
WO2007128480A3 (en) Thioglycosides as pharmaceutically active agents
BRPI0408727A (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar de uma condição ou estado de doença mediados pela atividade da quinase p38 ou mediados pelas citocinas produzidas pela atividade da quinase p38, e, uso de um composto
BRPI0416752B8 (pt) composição farmacêutica, uso de um ou mais compostos, e, compostos
BRPI0921097B8 (pt) composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
EP2170857A4 (en) 3 ', 4', 5-TRIMETHOXYFLAVONE DERIVATIVES AS THE SLEEP SECRETION STIMULATING AGENT, CORRESPONDING METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
BRPI0517438A (pt) composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]